Celsius Therapeutics

Celsius Therapeutics

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 1 - 10
  • Clinical stage: Clin1
  • Therapy area: IBD
  • Drug types: GI, IMM
  • Lead product: CEL383
  • Product link: https://celsiustx.com/pipeline/
  • Funding: $83M Mar 2022; $65M A May 2018
  • Investors: Third Rock



job board

Short description:

RNA sequencing for drug discovery, Antibody-drug conjugates

Drug notes:

Undisclosed RD IBD

Long description:

Celsius Therapeutics is leveraging the power of Single Cell Genomics and Machine Learning to develop precision medicines for cancer and autoimmune diseases. Dysfunctional cells can cause disease, but the exact problematic cells and their effect is often unclear. By looking at the genes expressed in single cells in their natural context, Celsius is developing machine learning algorithms to identify the specific cells that cause the disease and which genes/pathways are responsible. This helps to identify the best choices for drug combinations. With their global reach of tissue samples, industrialized workflow, and deep insights, Celsius’ mission is to develop life-saving medicines and discover critical biomarkers for better patient care by understanding the ecosystem of disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com